14:10~14:50 Current landscape of targeted therapy in advanced ALK-positive NSCLCbr/ 14:50~15:30 2L treatment options in ALK+ NSCLC patients under Taiwan reimbursement situationbr/ 15:30~15:50 休息br/ 15:50~16:30 Evolving Treatment Options for Patients with Refractory mCRC: from TKI to precision medicinebr/ 16:30~17:10 Targeted Therapies in Advanced Hepatocellular Carcinoma: Optimizing Outcomes with Sequential Treatmentbr/